Hexarelin Research Overview (also known as Examorelin, EP1572, GHRP-like hexarelin)
One of the most potent synthetic GH-releasing peptides, studied for its strong stimulation of GH secretion, muscle repair support, and potential cardioprotective effects. Research has also explored its influence on the cardiovascular system, including myocardial protection in stress models.
What Is Hexarelin?
Hexarelin is a synthetic hexapeptide GH secretagogue and potent agonist of the ghrelin/GHS-R1a receptor. It produces the highest GH-releasing potency among the GHRP family compounds, generating supraphysiological GH pulses at research doses. Beyond GH-releasing properties, Hexarelin has attracted significant attention for receptor-independent cardioprotective effects mediated through CD36 — a fatty acid translocase that serves as a secondary Hexarelin receptor in cardiac tissue.
GH-Releasing Mechanism
Hexarelin stimulates pituitary somatotrophs through GHSR-1a agonism and reduces hypothalamic somatostatin tone, producing extremely potent GH pulses. Its GH-releasing potency exceeds that of GHRP-6, GHRP-2, and Ipamorelin on a molar basis, though this comes with more pronounced GH-axis desensitization with frequent dosing compared to Ipamorelin.
Cardioprotective Effects via CD36
Hexarelin's most distinctive research property is its cardioprotection through CD36. In animal models of myocardial infarction, Hexarelin reduces infarct size, preserves ejection fraction, and promotes post-infarction cardiac remodeling. Importantly, this effect occurs even in GH-deficient and hypophysectomized animals — confirming it is independent of GH release and directly mediated by CD36 signaling in cardiomyocytes.
Quick Reference
| Literature-Reported Dose Range | 100 mcg (10 units if mixed at 100mcg/10 units) |
| Literature-Reported Frequency | 2-3 times daily for pulsatile GH release |
| Literature-Reported Cycle Length | 8-16 weeks maximum |
| Literature-Reported Washout | 4-6 weeks mandatory to restore GH response and prevent tolerance |
| Storage | Refrigerate at 2-8°C immediately after reconstitution. Use within 4 weeks. |
| Sites Reported in Studies | SubQ: Lower abdomen (2 inches from navel), outer thigh, back of upper arm |
| Timing | Morning upon waking, midday (optional), and 30 minutes before bed. Administer on empty stomach. |
Research Indications
Hormonal
Growth Hormone Release
Most potent GHRP studied, stimulating dose-dependent GH release with peak levels at 30 minutes post-injection
IGF-1 Elevation
Increases insulin-like growth factor 1 through enhanced pituitary GH secretion
Pulsatile GH Pattern
Preserves natural GH secretion rhythm when dosed appropriately throughout the day
Cardiovascular
Cardioprotection
Binds CD36 cardiac receptors, reducing infarct size and improving left ventricular function independent of GH
Anti-Fibrotic Effects
Reduces cardiac collagen deposition and fibrosis in heart failure models
Ischemia-Reperfusion Protection
Protects cardiac tissue from damage during ischemia and subsequent reperfusion
Neuroprotection
Neurogenesis Support
Promotes hippocampal neurogenesis and survival of new adult-born neurons
Anti-Apoptotic Effects
Protects neurons from oxidative stress-induced cell death through Bcl-2 and caspase modulation
ALS Research
Shows protective effects in ALS cell models by reducing oxidative damage and inflammation
Recovery
Muscle Preservation
Protects against chemotherapy-induced cachexia by improving mitochondrial function
Tissue Repair
Enhanced recovery through GH-mediated protein synthesis and cellular regeneration
Exercise Recovery
Supports post-workout recovery through growth factor cascade activation
Metabolic
Lipid Metabolism
Improves lipid profiles by decreasing triglycerides and supporting healthy fat metabolism
Insulin Sensitivity
Research indicates improvements in insulin sensitivity and glucose regulation
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| GH Optimization | 100 mcg | 3x daily (morning, midday, evening) | SubQ |
| Cardioprotection Research | 100-200 mcg | 2x daily | SubQ |
| Recovery/Anti-Aging | 100 mcg | 2x daily (morning and bedtime) | SubQ |
| With GHRH (Synergistic) | 100 mcg hexarelin + 100 mcg CJC-1295 | 2-3x daily | SubQ |
Timing
Morning upon waking, midday (optional), and 30 minutes before bed. Administer on empty stomach. Typical onset: gH peak at 30 minutes, IGF-1 elevation in 1-2 weeks, body composition changes in 4-8 weeks. Desensitization begins week 4.
Peptide Interactions
GHRP + GHRH combination provides complementary GH release through different receptor pathways. Studies show synergistic peak GH secretion rates greater than the arithmetic sum of isolated administration.
GHRH analog enhances hexarelin's pulsatile GH release. Research demonstrates synergistic effects when co-administered, though synergy diminishes with repeated dosing.
Both are GHRPs with different selectivity profiles. Combining may soften hexarelin's cortisol/prolactin elevation while maintaining GH output through complementary receptor activity.
Both GHRPs stimulate GH through similar pathways. Combination may cause excessive GH spikes and additive side effects including cortisol and prolactin elevation.
Structurally similar GHRPs with overlapping mechanisms. Combining provides diminishing returns with increased risk of hormonal side effects.
DAC version provides continuous GH elevation which may conflict with hexarelin's pulsatile release pattern, potentially reducing synergistic benefits and accelerating desensitization.
Both stimulate GH through ghrelin receptor. MK-677's continuous oral action combined with hexarelin may lead to excessive and prolonged GH elevation requiring monitoring.
FDA-approved GHRH analog works through complementary pathway. Studies on GHRH + hexarelin combinations show synergistic GH release significantly greater than either alone.
Exogenous HGH suppresses natural GH release pathways. Combining defeats hexarelin's purpose and may cause excessive GH levels with increased side effects.
Different mechanisms with no known interactions. BPC-157's tissue repair properties may complement hexarelin's recovery and cardioprotective effects.
Reported Research Timeline
01Day 1–7 (reported in cited studies): improved sleep quality, potential facial flushing post-injection, increased appetite possible
02Week 2–4 (reported in cited studies): enhanced recovery from exercise, improved skin quality, beginning of body composition changes
03Week 4–8 (reported in cited studies): noticeable improvements in lean mass and fat loss, some desensitization may begin
04Week 8–12 (reported in cited studies): continued benefits but GH response reduced 40-50% from baseline
05Week 12–16 (reported in cited studies): maximum cycle length - take mandatory 4-6 week break to restore sensitivity
06Post-cycle: GH response recovers to near-baseline within 4 weeks off
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Most potent GHRP but also highest side effect profile among GHRPs
Elevates cortisol and prolactin at standard doses - unlike Ipamorelin
May cause water retention, particularly in first 1-2 weeks
Can affect glucose metabolism - monitor if diabetic or pre-diabetic
Not recommended for those with active cancer due to growth-promoting effects
WADA prohibited substance - banned in competitive sports
Secondary hypogonadism possible with prolonged use due to prolactin elevation
Partial desensitization is normal and reversible with cycling
Seek Medical Attention If:
Persistent joint pain or carpal tunnel symptoms (indicates excessive GH)
Severe water retention or edema not resolving after 2 weeks
Signs of gynecomastia (from elevated prolactin)
Significant fatigue or lethargy
Blood glucose dysregulation
Unexplained headaches or vision changes
Any signs of allergic reaction at injection sites
Quality Indicators
Verified Marker
Third-party COA verification
Purchase from vendors providing certificates of analysis showing >98% purity and correct molecular weight (887 Da)
Verified Marker
Proper cold chain shipping
Peptide should arrive with ice packs in insulated packaging, especially in warm weather
Verified Marker
Vacuum-sealed vials
Legitimate products create vacuum when reconstituted - water should be drawn into vial
Acceptable Range
Monitor for desensitization
GH response decreases over time - follow cycling protocols strictly
Acceptable Range
Cortisol and prolactin effects
Unlike Ipamorelin, hexarelin can elevate cortisol and prolactin - monitor if using long-term
Quality Concern
Pre-mixed solutions
Avoid pre-reconstituted products - hexarelin degrades rapidly in solution
Quality Concern
Discolored or cloudy solution
Solution must be clear - any discoloration indicates degradation
Research Citations
- Growth hormone-releasing activity of hexarelin in humans. A dose-response study
Imbimbo, B.P., Mant, T., Edwards, M., Heber, D., Enghild, J., Melman, N., et al., 1994, European Journal of Clinical Pharmacology - Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction
McDonald, H., Peart, J., Kurniawan, N., Galloway, G., Royce, S., Samuel, C.S., Chen, C., 2018, Physiological Reports - Protective Effects of Hexarelin and JMV2894 in a Human Neuroblastoma Cell Line Expressing the SOD1-G93A Mutated Protein
Meanti, R., Licata, M., Rizzi, L., Bresciani, E., Molteni, L., Coco, S., et al., 2023, International Journal of Molecular Sciences - Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat
Xu, X., Ding, F., Pang, J., Gao, X., Xu, R.K., Hao, W., et al., 2012, American Journal of Physiology - Heart and Circulatory Physiology - Growth hormone-independent cardioprotective effects of hexarelin in the rat
Locatelli, V., Rossoni, G., Schweiger, F., Torsello, A., De Gennaro Colonna, V., Bernareggi, M., et al., 1999, Endocrinology - Growth hormone secretagogues and the regulation of calcium signaling in muscle
Bresciani, E., Rizzi, L., Coco, S., Molteni, L., Meanti, R., Locatelli, V., Torsello, A., 2019, International Journal of Molecular Sciences - The cardiovascular action of hexarelin
Marleau, S., Bherer, P., Bherer, L., Bherer, J., 2006, Journal of Endocrinological Investigation - Growth hormone secretagogues: history, mechanism of action, and clinical development
Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S.D., von Haehling, S., 2020, JCSM Rapid Communications
Research Focus
Growth hormone release, Cardioprotection, GHS-R agonism, Muscle mass, Anti-aging
Verified Vendors Carrying Hexarelin
Frequently Asked Questions
What should researchers watch for with Hexarelin?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Hexarelin?
Day 1–7 (reported in cited studies): improved sleep quality, potential facial flushing post-injection, increased appetite possible
How is Hexarelin typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →